Imiquimod + Diclofenac
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Actinic Keratosis
Conditions
Actinic Keratosis
Trial Timeline
Dec 1, 2008 → Nov 1, 2012
NCT ID
NCT00777127About Imiquimod + Diclofenac
Imiquimod + Diclofenac is a approved stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00777127. Target conditions include Actinic Keratosis.
What happened to similar drugs?
6 of 20 similar drugs in Actinic Keratosis were approved
Approved (6) Terminated (1) Active (14)
🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01453179 | Approved | Completed |
| NCT00777127 | Approved | Completed |
Competing Products
20 competing products in Actinic Keratosis